Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Watson Laboratories Files ANDA To Market Nebivolol Hydrochloride Tablets

RELATED NEWS
Trade ACT now with 

Watson Laboratories Inc., a subsidiary of Watson Pharmaceuticals Inc. (WPI: Quote), has filed an Abbreviated New Drug Application with the FDA seeking approval to market Nebivolol Hydrochloride Tablets, the generic version of Forest Laboratories' Bystolic.

Bystolic is a beta-adrenergic blocking agent that is approved for the treatment of hypertension.

Forest Laboratories filed suit against Watson on March 13 in the US District Court of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent.

Watson said it might be the first applicant to file an ANDA for the generic version of Bystolic and if approved it will be entitled to 180 days of generic market exclusivity.

Click here to receive FREE breaking news email alerts for Actavis Plc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Alaska Congressman Don Young, R-Ak., is once again making headlines with comments linking the state's high suicide rate to an increase in government assistance. Young told an audience at a senior center on Wednesday that the suicide problem didn't exist until there was "largesse" from the government. After moving sharply higher at the open, stocks have seen further upside over the course of the trading day on Thursday. The strong upward move on the day has more than offset the pullback that was seen in the previous session. Suggesting moderate growth in the short-term, the Conference Board released a report on Thursday showing that its index of leading U.S. economic indicators rose by more than economists had anticipated in the month of September.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.